Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR

Rang in Aktien #36458
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Aktienkurs
$1.73
Zuletzt synchronisiert: 2025-06-17
Marktkapitalisierung
$2.55M
Veränderung (1 Tag)
-0.29%
Veränderung (1 Jahr)
-79.71%
Land
US
Handel Eiger BioPharmaceuticals, Inc. (EIGR)

Kategorie

Healthcare
Aktien-Split-Historie für Eiger BioPharmaceuticals, Inc. (EIGR)
Die Aktie Eiger BioPharmaceuticals, Inc. (Symbol: EIGR) durchlief insgesamt 2 Aktiensplits.
Der letzte Aktiensplit fand am Jan 08, 2024 statt.
Eine EIGR-Aktie, die vor dem Mar 23, 2016 gekauft wurde, entspricht heute 0.0022222222222222 EIGR-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
2024-01-08 1:30 x0.033333333333333 x0.0022222222222222
2016-03-23 1:15 x0.066666666666667 x0.066666666666667
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL